Lunai Bioworks Inc. Business Combination, Contingent Consideration, Liability
Lunai Bioworks Inc. (LNAI) had Business Combination, Contingent Consideration, Liability of $1.32 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2025-05-15
- 2025-03-31: Business Combination, Contingent Consideration, Liability $1.32M.
- 2024-06-30: Business Combination, Contingent Consideration, Liability $12.31M.
- 2023-09-30: Business Combination, Contingent Consideration, Liability $0.00.
- 2022-09-30: Business Combination, Contingent Consideration, Liability $419.18K.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2025-03-31 | $1.32M 10-Q · filed 2025-05-15 |
| 2024-06-30 | $12.31M 10-Q · filed 2025-05-15 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 |
| 2022-09-30 | $419.18K 10-Q · filed 2023-11-14 |
| 2021-03-31 | $2.95M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $2.07M 10-Q · filed 2021-02-16 |
| 2020-09-30 | $2.76M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $3.18M 10-Q · filed 2021-05-17 |
| 2020-03-31 | $2.01M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $4.32M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $5.40M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $5.67M 10-Q · filed 2020-05-11 |
| 2018-06-30 | $22.89M 10-K · filed 2019-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |